The development and validation of a new HPLC-MS/MS method for the combined determination of the DDAH1 inhibitor ZST316 and its active metabolite L-257 allowed a comprehensive characterization of the pharmacokinetics and tumour distribution of both compounds after acute and chronic treatment with ZST316. The gene discussed is DDAH1; the disease is neoplasm.